Drug Search Results
More Filters [+]

QLG-2198

Alternative Names: QLG-2198, QLG 2198, QLG2198
Latest Update: 2024-06-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Qilu Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for QLG-2198

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Pruritus

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

QLG2198-301

P3

Recruiting

Pruritus

2025-02-21

70%

Recent News Events

Date

Type

Title